Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment

Next Previous
Trial Profile

The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ARDENT

    • Most Recent Events

    • 30 Jul 2021 Results of ancillary study of this study assessing effects of anti retroviral drugs on changes in lipid profile published in the Medicine.
    • 19 Apr 2021 Results assessing the Association Between Weight Gain, Sex and Immune Activation Following the Initiation of Antiretroviral Therapy from two trials A5202 and A5257 published in the Journal of Infectious Diseases
    • 07 Mar 2018 Results of analysis assessing hair antiretroviral levels as a predictor of virologic outcomes presented at the 25th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top